Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380371823> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4380371823 endingPage "i5" @default.
- W4380371823 startingPage "i5" @default.
- W4380371823 abstract "Abstract Rare embryonal tumors (excluding medulloblastoma and ATRT) are aggressive pediatric cancers that include embryonal tumor with multilayer rosettes (ETMR), embryonal tumor with abundant neuropil and true rosettes (ETANTR), and embryonal tumors not otherwise specified (ET-NOS). The presence of driver events like C19MC amplification, DICER1 mutations and other microRNA-related aberrations are vital in diagnostic classification of these tumors. The prognosis of these tumors is dismal despite intensive multimodal treatments with the 5-year overall survival being less than 30%. We retrospectively reviewed 12 patients with rare embryonal tumors who were treated at MD Anderson Cancer Center from 2010 to 2022. Of the 12 patients identified, the mean age at diagnosis was 3.6 years (range: 1-12 years) with no sex differences. Histologically, they were classified into ETMR (4/12), ETANTR (3/12) and ET-NOS (5/12) with C19MC found positive in 2/4 ETMR cases. All patients presented with large infiltrative tumors to the supratentorial (6/12), brainstem (4/12), and spinal (2/12) regions. The majority of patients (10/12) were treated by gross/subtotal resection. Treatment at diagnosis included surgery alone (3/12), surgery with chemotherapy (4/12), surgery with chemotherapy plus radiation (4/12),and chemotherapy plus radiation without surgery (1/12). Five patients reported with de-novo metastasis and 10/12 patients had disease progression at 4.1 months of median follow-up (range: 1.2-10.6 months). Six patients had local recurrence and three patients had local with distant disease at progression. Eight patients are still alive, with 5/8 of them surviving more than 5 years. In conclusion, these rare embryonal tumors are hard to diagnose and treat effectively. Even with successful surgery and intense chemotherapy, almost all of them progress/relapse but combined treatments seem to be effective in a subset of patients. Collaborative multi-institutional efforts are required to define standard treatment approaches and future patient stratification." @default.
- W4380371823 created "2023-06-13" @default.
- W4380371823 creator A5005106229 @default.
- W4380371823 creator A5014091805 @default.
- W4380371823 creator A5015150415 @default.
- W4380371823 creator A5017360357 @default.
- W4380371823 creator A5031795097 @default.
- W4380371823 creator A5075404207 @default.
- W4380371823 creator A5078349984 @default.
- W4380371823 creator A5089705538 @default.
- W4380371823 date "2023-06-01" @default.
- W4380371823 modified "2023-09-26" @default.
- W4380371823 title "ATRT-19. RARE EMBRYONAL TUMORS INCLUDING EMBRYONAL TUMOR MULTILAYER ROSETTE, OUTCOME AND PATTERN OF TREATMENT FAILURE: MD ANDERSON CANCER CENTER EXPERIENCE" @default.
- W4380371823 doi "https://doi.org/10.1093/neuonc/noad073.019" @default.
- W4380371823 hasPublicationYear "2023" @default.
- W4380371823 type Work @default.
- W4380371823 citedByCount "0" @default.
- W4380371823 crossrefType "journal-article" @default.
- W4380371823 hasAuthorship W4380371823A5005106229 @default.
- W4380371823 hasAuthorship W4380371823A5014091805 @default.
- W4380371823 hasAuthorship W4380371823A5015150415 @default.
- W4380371823 hasAuthorship W4380371823A5017360357 @default.
- W4380371823 hasAuthorship W4380371823A5031795097 @default.
- W4380371823 hasAuthorship W4380371823A5075404207 @default.
- W4380371823 hasAuthorship W4380371823A5078349984 @default.
- W4380371823 hasAuthorship W4380371823A5089705538 @default.
- W4380371823 hasBestOaLocation W43803718231 @default.
- W4380371823 hasConcept C121608353 @default.
- W4380371823 hasConcept C126322002 @default.
- W4380371823 hasConcept C141071460 @default.
- W4380371823 hasConcept C142724271 @default.
- W4380371823 hasConcept C143998085 @default.
- W4380371823 hasConcept C2776694085 @default.
- W4380371823 hasConcept C2779013556 @default.
- W4380371823 hasConcept C2780789225 @default.
- W4380371823 hasConcept C509974204 @default.
- W4380371823 hasConcept C71924100 @default.
- W4380371823 hasConceptScore W4380371823C121608353 @default.
- W4380371823 hasConceptScore W4380371823C126322002 @default.
- W4380371823 hasConceptScore W4380371823C141071460 @default.
- W4380371823 hasConceptScore W4380371823C142724271 @default.
- W4380371823 hasConceptScore W4380371823C143998085 @default.
- W4380371823 hasConceptScore W4380371823C2776694085 @default.
- W4380371823 hasConceptScore W4380371823C2779013556 @default.
- W4380371823 hasConceptScore W4380371823C2780789225 @default.
- W4380371823 hasConceptScore W4380371823C509974204 @default.
- W4380371823 hasConceptScore W4380371823C71924100 @default.
- W4380371823 hasIssue "Supplement_1" @default.
- W4380371823 hasLocation W43803718231 @default.
- W4380371823 hasLocation W43803718232 @default.
- W4380371823 hasOpenAccess W4380371823 @default.
- W4380371823 hasPrimaryLocation W43803718231 @default.
- W4380371823 hasRelatedWork W1946468667 @default.
- W4380371823 hasRelatedWork W2003938723 @default.
- W4380371823 hasRelatedWork W2047967234 @default.
- W4380371823 hasRelatedWork W2064166706 @default.
- W4380371823 hasRelatedWork W2087140558 @default.
- W4380371823 hasRelatedWork W2135275068 @default.
- W4380371823 hasRelatedWork W2382209557 @default.
- W4380371823 hasRelatedWork W2404042595 @default.
- W4380371823 hasRelatedWork W2439875401 @default.
- W4380371823 hasRelatedWork W2894984796 @default.
- W4380371823 hasVolume "25" @default.
- W4380371823 isParatext "false" @default.
- W4380371823 isRetracted "false" @default.
- W4380371823 workType "article" @default.